PB2112: MINDWAY: A PHASE IB/II DOSE OPTIMIZATION STUDY TO ASSESS SAFETY AND PHARMACOKINETICS OF TAFASITAMAB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

• R. Greil,
• K. Kopeckova,
• L. Arcaini,
• A. Amin,
• K. de Graaf,
• A.-M. Jegg

Affiliations

R. Greil

1 Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT); Cancer Cluster, Salzburg, Austria

K. Kopeckova

2 Department of Oncology of the 2nd Faculty of Medicine, Charles University and Motol University Hospital, Praha, Czechia

L. Arcaini

3 Division of Hematology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy

A. Amin

4 MorphoSys AG, Planegg, Germany

K. de Graaf

4 MorphoSys AG, Planegg, Germany

A.-M. Jegg

4 MorphoSys AG, Planegg, Germany